Minocin Injection (Minocycline Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news
Minocin (Minocycline Hydrochloride Oral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news
Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults
This Cochrane Review informed a practice changing update on Dynamed Plus. It found that antimicrobial coatings that appear to reduce risk of central venous catheter-related bloodstream infection include minocycline-rifampicin, chlorhexidine silver sulfadiazine, silver, and heparin, but antimicrobial coatings do not appear to reduce risk of sepsis or mortality (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2016 Category: Consumer Health News Source Type: news
minocycline (Dynacin, Minocin)
Title: minocycline (Dynacin, Minocin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 9/14/2016 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - September 14, 2016 Category: Dermatology Source Type: news
Minocin Capsules (Minocycline) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2016 Category: Drugs & Pharmacology Source Type: news
BioPharmX begins patient enrolment in Phase IIb OPAL study of BPX-01 to treat acne vulgaris
US-based pharmaceutical company BioPharmX has enrolled the first patient in its Phase IIb tOPicAL Minocycline Gel (OPAL) clinical trial of BPX-01 to treat acne vulgaris. (Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2016 Category: Pharmaceuticals Source Type: news
MassDevice.com +5 | The top 5 medtech stories for June 22, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. J&J investor relations veep Mehrotra retires, Wolk steps up
Johnson & Johnson said today its 10-year vice president of investor relations Louise Mehrotra will retire, effective January 2017, to be replaced by Joseph Wol...
Source: Mass Device - June 22, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
FDA warns Medtronic’s Tyrx on anti-bacterial envelopes
The FDA sent a warning letter earlier this month to Medtronic (NYSE:MDT) subsidiary Tyrx over problems with its process validation and quality systems.
The Tyrx envelopes are designed to elute a pair of anti-microbial drugs, minocycline and rifampin, for 7 days before dissolving over a period of roughly 9 weeks. They’re cleared for use with pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, deep-brain stimulators, sacral nerve stimulators, spinal cord stimulators and vagus nerve stimulators. Tyrx, which Medtronic acquired for $160 million in January 2014, won CE Mark...
Source: Mass Device - June 22, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Regulatory/Compliance Surgical Medtronic TYRX Inc. Warning Letter Source Type: news
Adjunctive minocycline microspheres
The aim of this study was to compare the effects of adjunctive Minocycline HCl Microspheres (Arestin) with debridement alone on the levels of 40 subgingival bacterial species in the treatment of peri-implantitis. Reseachers recruited 208 subjects (from 11 centers in the USA) with at least 1 implant with peri-implantitis and randomized to receive either mechanical debridement alone (n=104) or mechanical debridement followed by Arestin (1 mg) (n=104) at baseline and day 90. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 20, 2016 Category: Science Source Type: news
Meibomian Gland Dysfunction: Poor Evidence for Oral Antibiotics Meibomian Gland Dysfunction: Poor Evidence for Oral Antibiotics
More research is needed to define the role of doxycycline, minocycline, and azithromycin in this difficult-to-treat condition. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Old Drug Has New Promise in MSOld Drug Has New Promise in MS
Minocycline, an antibiotic that has been around for decades, reduced the risk for progression from clinically isolated syndrome to definite multiple sclerosis in a new study. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 14, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Tried-and-True Antibiotic May Block Conversion to MS (CME/CE)
(MedPage Today) -- Minocycline seemed to reduce progression to multiple sclerosis after first demyelinating event (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 10, 2015 Category: Neurology Source Type: news
FDA clears Medtronic’s Tyrx envelope for DBS devices
Medtronic (NYSE:MDT) said today that it’s launching its Tyrx surgical envelope in the U.S. for use with deep-brain stimulation devices, after it won 510(k) clearance from the FDA for use of the infection-fighting envelope with implantable neurostimulators.
Fridley, Minn.-based Medtronic said it’s planning to make the Tyrx device, acquired for $160 million in January 2014, available for other neurostim indications “in the coming months.”
The device is designed to elute a pair of anti-microbial drugs, minocycline and rifampin, for 7 days. The envelope is designed to then dissolve over a period of r...
Source: Mass Device - October 8, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Surgical Medtronic TYRX Inc. Source Type: news
What Are Common Drug Eruptions in Children?
Discussion
Drug reactions unfortunately are common in children and adults. These reactions have different but often overlapping appearances. Viral exanthams also often cloud the picture as these rashes can be because of the drug, the virus or both.
Patients with urticaria multiforme present with an acute rash that appears as urticaria plaques that have a hemorrhagic or dusky discoloration. It occurs 1-3 days after viral symptoms (including cough, rhinorrhea, diarrhea) and may also present with fever.
Morbilliform drug eruptions one of the most common drug reactions in children and usually occur 7-14 days after the onset ...
Source: PediatricEducation.org - July 27, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Medical device companies boost guarantees to hospitals
Medical device companies are reportedly boosting their guarantees to hospital customers, seeking to bolster flagging sales growth and downward price pressure, offering to compensate them if their devices fail to perform.
Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ) and St. Jude Medical (NYSE:STJ) are among the 1st to provide the newer guarantees, some of which offer to share in the cost of follow-up treatment tied to their heart devices, company executives told Reuters. Orthopedic device companies are also mulling similar guarantees for their hip and knee implants.
But even that may not be enough for some hos...
Source: Mass Device - July 8, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Business/Financial News BioSense Webster Inc. Ethicon Inc. Johnson & Johnson medtronic St. Jude Medical Source Type: news
